Capitalizing on Scientific Progress: Investment in HIV Prevention R&D in 2010

This annual accounting of funding for biomedical HIV prevention research tracks trends and identifies gaps in investment. The 2011 report describes the funding environment in the wake of a number of the findings of efficacy in the RV144, CAPRISA, iPrEx and HPTN 025 trials and calls for sustained funding to build on these results.

Accelerating Product Innovation
Tracking and Translating the Field